Coming up blanks on tyk2 sri grant funding. No record i can find on the NIH database of grants in the US. Sareum have referred to it as "us government funding" Sri international have no mention on their site. An outfit called "innovation pathways" look to have co authored the grant application. And state its NIH but dont mention lupus but "unmet clinical need". Previous SRI grants in tyk2 have been in sepsis and department if defence grants (bio terror). And sri have received a bid chunk of new defence funding. Nih funding is usually pretty transparent with publicly searchable info. Why cant i find the supposed $360k grant.? If anyone can find it much appreciated. I can normally find anything as you know. But it seems hidden.....
Ta Thoth.....agree 100%....28p seems a lot but nothing compared to market......the thought of a £1 seems to me scary lol.....but agree could happen if we tick all boxes. Also agree the more combo trials the bettter the chance of more synergistic alliance within other drugs
Im sticking with 28p. Others have failed in chk2 due to toxicity. Ditto aurora. And it has limited the Jak class. If we are more selective and therefore less side effects and sail through phase1s 28p is conservative. If phase1 all fail worth sod all. 28p is c 700m valuation. Which would be achieved on a licence revenue of c 50m a year. Which on a ten percent royalty implies medicine sales of 500m p.a. I think chk1 is $2bn a year sales minimum. And i dont see tyk2 being less. So if all 3 fail early worth not much. All 3 do well could be a quid in a few years. And every permutation in between. But the more combo trials we do in the more indications reduces risk for me. If chk1 failed as a single agent for example. It may still be the best treatment option with another parp inhibitor in a specific cancer type. Sierras approach is great. I hope we will do similar in tyk2. The more combo trials we do the lower the risk of a compound failure as it may end up being best for some cancers and not others and still progress in those indications. Bit long . Sorry.
I hope you are right mate, you deserve it more than most, great research, great dedication. I also appreciate your information sharing. June would be ideal for me, I could actually retire and relax for a change. I know you mentioned June a while ago, but things happen, as long as you think there is still a possibility of great news in June, that's fine by me. Please keep up the good work and good luck.
Thanks Thoth....,much appreciated. Speaks volumes that you are still happy to do research for us other humble investors ...fingers crossed this comes off and will be lovely to meet up with some of the decent people here one day to celebrate.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.